Combined versus Sequential Pars Plana Vitrectomy and Phacoemulsification for Macular Hole and Epiretinal Membrane

医学 玻璃体切除术 超声乳化术 扁平部 视网膜前膜 眼科 黄斑水肿 置信区间 视力 随机对照试验 荟萃分析 相对风险 外科 内科学
作者
Fowad Daud,Kashif Daud,Marko Popović,Shanna C. Yeung,Yuyi You,Miguel Cruz-Pimentel,Peng Yan
出处
期刊:Ophthalmology Retina [Elsevier]
卷期号:7 (8): 721-731 被引量:2
标识
DOI:10.1016/j.oret.2023.03.017
摘要

Comparing the efficacy and safety between combined and sequential pars plana vitrectomy and phacoemulsification for macular hole (MH) and epiretinal membrane (ERM).The standard of care for MH and ERM is vitrectomy, which increases the risk of developing cataract. Combined phacovitrectomy eliminates the need for a second surgery.Ovid MEDLINE, EMBASE, and Cochrane CENTRAL were searched in May 2022 for all articles comparing combined versus sequential phacovitrectomy for MH and ERM. The primary outcome was mean best-corrected visual acuity (BCVA) at 12 months follow-up. Meta-analysis was conducted using a random effects model. Risk of bias (RoB) was assessed using the Cochrane RoB 2 tool for randomized controlled trials (RCTs) and Risk of Bias in Nonrandomized Studies of Interventions tool for observational studies (PROSPERO, registration number, CRD42021257452).Of the 6470 studies found, 2 RCTs and 8 nonrandomized retrospective comparative studies were identified. Total eyes for combined and sequential groups were 435 and 420, respectively. Meta-analysis suggested no significant difference between combined and sequential surgery for 12-month BCVA (combined = 0.38 logarithm of the minimum angle of resolution [logMAR]; sequential = 0.36 logMAR; mean difference = + 0.02 logMAR; 95% confidence interval = -0.04 to 0.08; P = 0.51; I2 = 0%; n = 4 studies, 398 participants), as well as absolute refractive error (P = 0.76; I2 = 97%; n = 4 studies, 289 participants), risk of myopia (P = 0.15; I2 = 66%; n = 2 studies, 148 participants), MH nonclosure (P = 0.57; I2 = 48%; n = 4 studies, 321 participants), cystoid macular edema (P = 0.15; I2 = 0%; n = 6 studies, 526 participants), high-intraocular pressure (P = 0.09; I2 = 0%; n = 2 studies, 161 participants), posterior capsule opacification (P = 0.46; I2 = 0%; n = 2 studies, 161 participants), posterior capsule rupture (P = 0.41; I2 = 0%; n = 5 studies, 455 participants), and retinal detachment (P = 0.67; I2 = 0%; n = 6 studies, 545 participants).No significant difference was detected between combined and sequential surgeries for visual outcomes, refractive outcomes, or complications. Given that most studies were retrospective and contained a high RoB, future high-quality RCTs are warranted.Proprietary or commercial disclosure may be found after the references.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
4秒前
毛毛完成签到,获得积分10
4秒前
4秒前
6秒前
rl完成签到,获得积分10
7秒前
666666666666666完成签到,获得积分10
9秒前
归零儿完成签到,获得积分10
10秒前
天真的皓轩完成签到,获得积分10
10秒前
勤恳函完成签到,获得积分10
10秒前
古蓦然完成签到,获得积分10
10秒前
12秒前
13秒前
一二发布了新的文献求助10
13秒前
现实的筮完成签到,获得积分10
13秒前
17秒前
17秒前
上官若男应助耿继生采纳,获得10
17秒前
彭于晏应助jie采纳,获得10
19秒前
凡仔发布了新的文献求助10
21秒前
香蕉觅云应助可爱的采纳,获得10
22秒前
老实的不凡完成签到,获得积分10
23秒前
24秒前
26秒前
27秒前
sptyzl完成签到 ,获得积分10
28秒前
huhu完成签到 ,获得积分10
28秒前
28秒前
CipherSage应助凡仔采纳,获得10
29秒前
眯眯眼的不斜完成签到,获得积分10
30秒前
31秒前
耿继生发布了新的文献求助10
32秒前
33秒前
常泽洋122完成签到,获得积分10
38秒前
云_123发布了新的文献求助10
38秒前
gaobowang发布了新的文献求助10
38秒前
39秒前
深海渔完成签到,获得积分10
40秒前
argon完成签到,获得积分10
40秒前
41秒前
高分求助中
Sustainability in Tides Chemistry 2800
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
Rechtsphilosophie 1000
Bayesian Models of Cognition:Reverse Engineering the Mind 888
Le dégorgement réflexe des Acridiens 800
Defense against predation 800
Very-high-order BVD Schemes Using β-variable THINC Method 568
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3134988
求助须知:如何正确求助?哪些是违规求助? 2785963
关于积分的说明 7774538
捐赠科研通 2441779
什么是DOI,文献DOI怎么找? 1298177
科研通“疑难数据库(出版商)”最低求助积分说明 625088
版权声明 600825